In this issue:
British Association of Dermatologists biologic therapy guidelines
Biologics and COVID-19 risk
Meta-analysis of biologic therapies in psoriasis
Tralokinumab for moderate-to-severe atopic dermatitis
Subcutaneous brodalumab for hidradenitis suppurativa
Secukinumab 2-weekly vs 4-weekly dosing
Ustekinumab for moderate-to-severe paediatric plaque psoriasis
Secukinumab in paediatric patients with severe chronic plaque psoriasis
Dupilumab + topical corticosteroids in children with severe atopic dermatitis
Language proficiency and access to biologics
Please login below to download this issue (PDF)